Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Short-term Investments (2020 - 2025)

Rapid Micro Biosystems' Short-term Investments history spans 6 years, with the latest figure at $18.3 million for Q4 2025.

  • On a quarterly basis, Short-term Investments fell 45.99% to $18.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.3 million, a 45.99% decrease, with the full-year FY2025 number at $18.3 million, down 45.99% from a year prior.
  • Short-term Investments hit $18.3 million in Q4 2025 for Rapid Micro Biosystems, down from $22.3 million in the prior quarter.
  • Over the last five years, Short-term Investments for RPID hit a ceiling of $94.4 million in Q2 2022 and a floor of $1.2 million in Q1 2022.
  • Historically, Short-term Investments has averaged $42.5 million across 5 years, with a median of $33.8 million in 2024.
  • Biggest five-year swings in Short-term Investments: surged 7342.51% in 2022 and later tumbled 60.14% in 2025.
  • Tracing RPID's Short-term Investments over 5 years: stood at $15.1 million in 2021, then skyrocketed by 439.93% to $81.6 million in 2022, then dropped by 16.93% to $67.8 million in 2023, then crashed by 50.09% to $33.8 million in 2024, then tumbled by 45.99% to $18.3 million in 2025.
  • Business Quant data shows Short-term Investments for RPID at $18.3 million in Q4 2025, $22.3 million in Q3 2025, and $12.9 million in Q2 2025.